ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 239 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2021. The put-call ratio across all filers is 1.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $455,840 | -0.5% | 11,091 | +13.0% | 0.01% | 0.0% |
| Q1 2024 | $458,122 | -5.7% | 9,812 | -3.4% | 0.01% | -16.7% |
| Q4 2023 | $485,947 | +43.3% | 10,162 | +6.8% | 0.01% | +20.0% |
| Q3 2023 | $339,174 | -22.3% | 9,514 | +0.6% | 0.01% | -16.7% |
| Q2 2023 | $436,436 | +42.5% | 9,461 | +23.9% | 0.01% | +50.0% |
| Q1 2023 | $306,244 | -14.3% | 7,637 | -1.0% | 0.00% | -33.3% |
| Q4 2022 | $357,436 | +35.9% | 7,715 | +21.3% | 0.01% | +20.0% |
| Q3 2022 | $263,000 | -31.7% | 6,361 | -1.3% | 0.01% | -37.5% |
| Q2 2022 | $385,000 | -7.0% | 6,446 | +13.2% | 0.01% | +14.3% |
| Q1 2022 | $414,000 | -13.9% | 5,696 | -0.4% | 0.01% | -12.5% |
| Q4 2021 | $481,000 | -5.1% | 5,718 | +1.7% | 0.01% | -20.0% |
| Q3 2021 | $507,000 | -8.2% | 5,621 | -3.0% | 0.01% | 0.0% |
| Q2 2021 | $552,000 | +117.3% | 5,794 | +215.2% | 0.01% | +66.7% |
| Q4 2020 | $254,000 | +23.9% | 1,838 | -30.0% | 0.01% | +20.0% |
| Q2 2020 | $205,000 | – | 2,627 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
| Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
| Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
| AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
| EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
| FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
| HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
| Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |